Effect of Pentoxifylline on diabetic neuropathy in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016051827965N1

Enrollment

Registered

2016-09-23

Start date

2016-03-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

The tablet of pentoxifylline 400 mg and 100 mg tablets B1 , twice a day.

Placebo

The tablet of pentoxifylline 400 mg and 100 mg tablets B1 , twice a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:type 2 diabetes over a year;age group40-75;Distal polyneuropathy resolutions based on questionnaires Michigan;HBA1C8% -10% Exclusion criteria:Kidney,liver,and heart failure based on the tests, history and physical exam;High blood pressure more than 160 mm Hg and advanced diabetic Retinopathy;The recent use of drugs for neuropathy {gabapentin , nortriptyline};Fever;Pergnancy and lactation;History of amputation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FBS. Timepoint: pre and early post-operation. Method of measurement: Based on Labratory.;HBA1C. Timepoint: pre and early post-operation. Method of measurement: Based on Labratory.	—

Secondary

Measure	Time frame
Distal polyneuropathy. Timepoint: Before and 4 months after the intervention. Method of measurement: Michigan Questionnaire A.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Hosseini

Medical University

dr.farhadhosseini@gmil.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026